A P Trollip1, D Moore2, J Coronel3, L Caviedes3, S Klages1, T Victor1, E Romancenco4, V Crudu4, K Ajbani5, V P Vineet5, C Rodrigues5, R L Jackson6, K Eisenach7, R S Garfein6, T C Rodwell8, E Desmond9, E J Groessl10, T G Ganiats11, A Catanzaro6. 1. Biomedical Sciences, Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Medical Research Council Centre for Molecular and Cellular Biology, Stellenbosch University, Cape Town, South Africa. 2. TB Centre and Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK; Laboratorio de Investigación de Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru. 3. Laboratorio de Investigación de Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru. 4. Microbiology and Morphology Laboratory, Phthisiopneumology Institute, Chisinau, Moldova. 5. Department of Microbiology, Parmanand Deepchand Hinduja National Hospital and Medical Research Centre Tertiary Care Hospital, Mumbai, India. 6. University of California San Diego School of Medicine, La Jolla, California, USA. 7. Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. 8. Division of Global Public Health, University of California San Diego School of Medicine, La Jolla, California, USA. 9. Mycobacteriology and Mycology Section, Microbial Diseases Laboratory, California Department of Public Health, Richmond, California, USA. 10. University of California San Diego, Veterans' Affairs San Diego Healthcare System, La Jolla, California, USA. 11. University of California San Diego Health Services Research Center, UCSD, La Jolla, California, USA.
Abstract
OBJECTIVE: To establish breakpoint concentrations for the fluoroquinolones (moxifloxacin [MFX] and ofloxacin [OFX]) and injectable second-line drugs (amikacin [AMK], kanamycin [KM] and capreomycin [CPM]) using the microscopic observation drug susceptibility (MODS) assay. SETTING: A multinational study conducted between February 2011 and August 2012 in Peru, India, Moldova and South Africa. DESIGN: In the first phase, breakpoints for the fluoroquinolones and injectable second-line drugs (n = 58) were determined. In the second phase, MODS second-line drug susceptibility testing (DST) as an indirect test was compared to MGIT™ DST (n = 89). In the third (n = 30) and fourth (n = 156) phases, we determined the reproducibility and concordance of MODS second-line DST directly from sputum. RESULTS: Breakpoints for MFX (0.5 μg/ml), OFX (1 μg/ml), AMK (2 μg/ml), KM (5 μg/ml) and CPM (2.5 μg/ml) were determined. In all phases, MODS results were highly concordant with MGIT DST. The few discrepancies suggest that the MODS breakpoint concentrations for some drugs may be too low. CONCLUSION: MODS second-line DST yielded comparable results to MGIT second-line DST, and is thus a promising alternative. Further studies are needed to confirm the accuracy of the drug breakpoints and the reliability of MODS second-line DST as a direct test.
OBJECTIVE: To establish breakpoint concentrations for the fluoroquinolones (moxifloxacin [MFX] and ofloxacin [OFX]) and injectable second-line drugs (amikacin [AMK], kanamycin [KM] and capreomycin [CPM]) using the microscopic observation drug susceptibility (MODS) assay. SETTING: A multinational study conducted between February 2011 and August 2012 in Peru, India, Moldova and South Africa. DESIGN: In the first phase, breakpoints for the fluoroquinolones and injectable second-line drugs (n = 58) were determined. In the second phase, MODS second-line drug susceptibility testing (DST) as an indirect test was compared to MGIT™ DST (n = 89). In the third (n = 30) and fourth (n = 156) phases, we determined the reproducibility and concordance of MODS second-line DST directly from sputum. RESULTS: Breakpoints for MFX (0.5 μg/ml), OFX (1 μg/ml), AMK (2 μg/ml), KM (5 μg/ml) and CPM (2.5 μg/ml) were determined. In all phases, MODS results were highly concordant with MGIT DST. The few discrepancies suggest that the MODS breakpoint concentrations for some drugs may be too low. CONCLUSION: MODS second-line DST yielded comparable results to MGIT second-line DST, and is thus a promising alternative. Further studies are needed to confirm the accuracy of the drug breakpoints and the reliability of MODS second-line DST as a direct test.
Authors: David A J Moore; Daniel Mendoza; Robert H Gilman; Carlton A W Evans; María-Graciela Hollm Delgado; Jose Guerra; Luz Caviedes; Daniel Vargas; Eduardo Ticona; Jaime Ortiz; Giselle Soto; Jose Serpa Journal: J Clin Microbiol Date: 2004-10 Impact factor: 5.948
Authors: Grant Theron; Jonny Peter; Richard van Zyl-Smit; Hridesh Mishra; Elizabeth Streicher; Samuel Murray; Rodney Dawson; Andrew Whitelaw; Michael Hoelscher; Surendra Sharma; Madhukar Pai; Robin Warren; Keertan Dheda Journal: Am J Respir Crit Care Med Date: 2011-04-14 Impact factor: 21.405
Authors: David A J Moore; Carlton A W Evans; Robert H Gilman; Luz Caviedes; Jorge Coronel; Aldo Vivar; Eduardo Sanchez; Yvette Piñedo; Juan Carlos Saravia; Cayo Salazar; Richard Oberhelman; Maria-Graciela Hollm-Delgado; Doris LaChira; A Roderick Escombe; Jon S Friedland Journal: N Engl J Med Date: 2006-10-12 Impact factor: 91.245
Authors: L Caviedes; T S Lee; R H Gilman; P Sheen; E Spellman; E H Lee; D E Berg; S Montenegro-James Journal: J Clin Microbiol Date: 2000-03 Impact factor: 5.948
Authors: Marinus Barnard; Rob Warren; Nico Gey Van Pittius; Paul van Helden; Marlein Bosman; Elizabeth Streicher; Gerrit Coetzee; Richard O'Brien Journal: Am J Respir Crit Care Med Date: 2012-10-18 Impact factor: 21.405
Authors: Donald G Catanzaro; Andre P Trollip; Marva Seifert; Sophia B Georghiou; Richard S Garfein; Timothy C Rodwell; Antonino Catanzaro; Kathleen D Eisenach Journal: Eur Respir J Date: 2017-04-05 Impact factor: 16.671
Authors: Naomi Hillery; Erik J Groessl; Andre Trollip; Donald Catanzaro; Lynn Jackson; Timothy C Rodwell; Richard S Garfein; S-Y Grace Lin; Kathleen Eisenach; Theodore G Ganiats; Daniel Park; Faramarz Valafar; Camilla Rodrigues; Valeriu Crudu; Thomas C Victor; Antonino Catanzaro Journal: Trials Date: 2014-11-06 Impact factor: 2.279
Authors: Antonino Catanzaro; Timothy C Rodwell; Donald G Catanzaro; Richard S Garfein; Roberta L Jackson; Marva Seifert; Sophia B Georghiou; Andre Trollip; Erik Groessl; Naomi Hillery; Valeriu Crudu; Thomas C Victor; Camilla Rodrigues; Grace Shou-Yean Lin; Faramarz Valafar; Edward Desmond; Kathleen Eisenach Journal: PLoS One Date: 2015-08-31 Impact factor: 3.240
Authors: Laura Martin; Jorge Coronel; Dunia Faulx; Melissa Valdez; Mutsumi Metzler; Chris Crudder; Edith Castillo; Luz Caviedes; Louis Grandjean; Mitzi Rodriguez; Jon S Friedland; Robert H Gilman; David A J Moore Journal: PLoS One Date: 2014-09-16 Impact factor: 3.240